-
Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE ScoreDJ Angiolillo, D Capodanno, N Danchin et al. -
Six Versus 12 Months of Dual Antiplatelet Therapy After Implantation of Biodegradable Polymer Sirolimus-Eluting Stent: Randomized Substudy of the I-LOVE-IT 2 TrialHan Y, Xu B, Xu K et al.
-
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical TrialB-K Kim, S-J Hong, TICO Investigators et al.
-
Dual Antiplatelet Therapy Duration: Reconciling the InconsistenciesCosta F, Windecker S, Valgimigli M.
-
Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trialValgimigli M, Campo G, Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators.
-
Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapyvan Rein N, Heide-Jørgensen U, Lijfering WM et al.
-
Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI StudyNL Pereira, CS Rihal, DYF So et al.
-
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPTPaolo Z; Liefke C; van der Heijden et al.
http://www.cbsmd.cn Contact us by cbs@cbsmd.cn
Copyright ⓒ CBSMD Nanjing China. All rights reserved.
